JP2021505655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505655A5 JP2021505655A5 JP2020547315A JP2020547315A JP2021505655A5 JP 2021505655 A5 JP2021505655 A5 JP 2021505655A5 JP 2020547315 A JP2020547315 A JP 2020547315A JP 2020547315 A JP2020547315 A JP 2020547315A JP 2021505655 A5 JP2021505655 A5 JP 2021505655A5
- Authority
- JP
- Japan
- Prior art keywords
- bischoline
- tetrathiomolybdate
- patient
- pharmaceutical composition
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FSWNJZRQQVVVJT-UHFFFAOYSA-L bis(sulfanylidene)molybdenum;2-hydroxyethyl(trimethyl)azanium;sulfanide Chemical compound [SH-].[SH-].S=[Mo]=S.C[N+](C)(C)CCO.C[N+](C)(C)CCO FSWNJZRQQVVVJT-UHFFFAOYSA-L 0.000 claims 54
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 22
- 108010082126 Alanine transaminase Proteins 0.000 claims 22
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 22
- 208000018839 Wilson disease Diseases 0.000 claims 22
- 208000014094 Dystonic disease Diseases 0.000 claims 10
- 206010044565 Tremor Diseases 0.000 claims 10
- 208000010118 dystonia Diseases 0.000 claims 10
- 210000000440 neutrophil Anatomy 0.000 claims 10
- 102000001554 Hemoglobins Human genes 0.000 claims 9
- 108010054147 Hemoglobins Proteins 0.000 claims 9
- 206010060860 Neurological symptom Diseases 0.000 claims 6
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims 5
- 230000005021 gait Effects 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000006866 deterioration Effects 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 235000020937 fasting conditions Nutrition 0.000 claims 2
- 206010003547 Asterixis Diseases 0.000 claims 1
- 206010064950 Head titubation Diseases 0.000 claims 1
- 208000008457 Neurologic Manifestations Diseases 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000030137 articulation disease Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000002662 enteric coated tablet Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023038205A JP2023075247A (ja) | 2017-12-04 | 2023-03-13 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
| JP2025010250A JP2025066802A (ja) | 2017-12-04 | 2025-01-24 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594184P | 2017-12-04 | 2017-12-04 | |
| US62/594,184 | 2017-12-04 | ||
| US201862646553P | 2018-03-22 | 2018-03-22 | |
| US62/646,553 | 2018-03-22 | ||
| US201862655568P | 2018-04-10 | 2018-04-10 | |
| US62/655,568 | 2018-04-10 | ||
| US201862669095P | 2018-05-09 | 2018-05-09 | |
| US62/669,095 | 2018-05-09 | ||
| US201862741313P | 2018-10-04 | 2018-10-04 | |
| US62/741,313 | 2018-10-04 | ||
| US201862750595P | 2018-10-25 | 2018-10-25 | |
| US62/750,595 | 2018-10-25 | ||
| PCT/EP2018/083551 WO2019110619A1 (en) | 2017-12-04 | 2018-12-04 | Bis-choline tetrathiomolybdate for treating wilson disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038205A Division JP2023075247A (ja) | 2017-12-04 | 2023-03-13 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505655A JP2021505655A (ja) | 2021-02-18 |
| JP2021505655A5 true JP2021505655A5 (enExample) | 2022-01-11 |
Family
ID=64661349
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547315A Pending JP2021505655A (ja) | 2017-12-04 | 2018-12-04 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
| JP2023038205A Pending JP2023075247A (ja) | 2017-12-04 | 2023-03-13 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
| JP2025010250A Pending JP2025066802A (ja) | 2017-12-04 | 2025-01-24 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038205A Pending JP2023075247A (ja) | 2017-12-04 | 2023-03-13 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
| JP2025010250A Pending JP2025066802A (ja) | 2017-12-04 | 2025-01-24 | ウィルソン病を治療するためのビスコリンテトラチオモリブデート |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11510944B2 (enExample) |
| EP (3) | EP4523745A3 (enExample) |
| JP (3) | JP2021505655A (enExample) |
| KR (1) | KR102803161B1 (enExample) |
| AU (1) | AU2018379255B2 (enExample) |
| BR (1) | BR112020011055A2 (enExample) |
| CA (1) | CA3084100A1 (enExample) |
| DK (2) | DK4029498T3 (enExample) |
| ES (2) | ES3026756T3 (enExample) |
| FI (1) | FI4029498T3 (enExample) |
| HU (2) | HUE058921T2 (enExample) |
| IL (1) | IL275115B2 (enExample) |
| MX (1) | MX2020006284A (enExample) |
| PL (2) | PL3720433T3 (enExample) |
| PT (2) | PT4029498T (enExample) |
| SI (2) | SI3720433T1 (enExample) |
| WO (1) | WO2019110619A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11419832B2 (en) * | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
| EP4523745A3 (en) * | 2017-12-04 | 2025-05-14 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating wilson disease |
| WO2019154876A1 (en) | 2018-02-06 | 2019-08-15 | Wilson Therapeutics Ab | Crystalline particles of bis-choline tetrathiomolybdate |
| US20220387370A1 (en) | 2019-11-21 | 2022-12-08 | Alexion Pharmaceuticals, Inc. | Methods of reducing neurological damage in wilson disease patients |
| WO2022056278A1 (en) * | 2020-09-11 | 2022-03-17 | Alexion Pharmaceuticals, Inc. | Anti-ceruloplasmin antibodies and uses thereof |
| CA3172751A1 (en) | 2020-11-13 | 2022-05-19 | Alexion Pharmaceuticals, Inc. | Methods of treating copper metabolism-associated diseases or disorders |
| EP4284361A4 (en) * | 2021-01-31 | 2025-03-19 | Alexion Pharmaceuticals, Inc. | Novel formulation for treating copper metabolism-associated diseases or disorders |
| EP4387631A1 (en) * | 2021-08-17 | 2024-06-26 | Alexion Pharmaceuticals, Inc. | Methods of treating copper metabolism-associated diseases or disorders |
| WO2024162974A1 (en) | 2023-01-30 | 2024-08-08 | Alexion Pharmaceuticals, Inc. | Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA008683B1 (ru) * | 2002-07-23 | 2007-06-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии |
| US7189865B2 (en) * | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
| CA2675230A1 (en) | 2006-01-10 | 2008-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US11419832B2 (en) * | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
| EP4523745A3 (en) | 2017-12-04 | 2025-05-14 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating wilson disease |
| WO2019154876A1 (en) | 2018-02-06 | 2019-08-15 | Wilson Therapeutics Ab | Crystalline particles of bis-choline tetrathiomolybdate |
-
2018
- 2018-12-04 EP EP25154707.1A patent/EP4523745A3/en active Pending
- 2018-12-04 KR KR1020207019115A patent/KR102803161B1/ko active Active
- 2018-12-04 EP EP21215264.9A patent/EP4029498B1/en active Active
- 2018-12-04 MX MX2020006284A patent/MX2020006284A/es unknown
- 2018-12-04 PT PT212152649T patent/PT4029498T/pt unknown
- 2018-12-04 PL PL18815624.4T patent/PL3720433T3/pl unknown
- 2018-12-04 DK DK21215264.9T patent/DK4029498T3/da active
- 2018-12-04 IL IL275115A patent/IL275115B2/en unknown
- 2018-12-04 HU HUE18815624A patent/HUE058921T2/hu unknown
- 2018-12-04 ES ES21215264T patent/ES3026756T3/es active Active
- 2018-12-04 JP JP2020547315A patent/JP2021505655A/ja active Pending
- 2018-12-04 HU HUE21215264A patent/HUE071155T2/hu unknown
- 2018-12-04 US US16/770,022 patent/US11510944B2/en active Active
- 2018-12-04 SI SI201830650T patent/SI3720433T1/sl unknown
- 2018-12-04 ES ES18815624T patent/ES2912306T3/es active Active
- 2018-12-04 CA CA3084100A patent/CA3084100A1/en active Pending
- 2018-12-04 PL PL21215264.9T patent/PL4029498T3/pl unknown
- 2018-12-04 FI FIEP21215264.9T patent/FI4029498T3/fi active
- 2018-12-04 WO PCT/EP2018/083551 patent/WO2019110619A1/en not_active Ceased
- 2018-12-04 DK DK18815624.4T patent/DK3720433T3/da active
- 2018-12-04 BR BR112020011055-8A patent/BR112020011055A2/pt unknown
- 2018-12-04 EP EP18815624.4A patent/EP3720433B1/en active Active
- 2018-12-04 PT PT188156244T patent/PT3720433T/pt unknown
- 2018-12-04 AU AU2018379255A patent/AU2018379255B2/en active Active
- 2018-12-04 SI SI201831229T patent/SI4029498T1/sl unknown
-
2021
- 2021-02-22 US US17/182,227 patent/US20210177894A1/en not_active Abandoned
-
2022
- 2022-08-23 US US17/821,786 patent/US12233088B2/en active Active
-
2023
- 2023-03-13 JP JP2023038205A patent/JP2023075247A/ja active Pending
-
2025
- 2025-01-24 JP JP2025010250A patent/JP2025066802A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505655A5 (enExample) | ||
| JP7424676B2 (ja) | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 | |
| US6596756B1 (en) | Treatment of fibromyalgia | |
| US20180235934A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| CN102056603A (zh) | 决奈达隆用于预防持续性心房纤颤 | |
| JP2017537089A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| AU2013237881B2 (en) | Dosage forms of halofuginone and methods of use | |
| AU2018219861A1 (en) | Methods of treating seizure disorders and prader-willi syndrome | |
| CN110974828B (zh) | 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物 | |
| JP2020536121A5 (enExample) | ||
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| BR112020007817A2 (pt) | método de uso e composições contendo dulaglutido | |
| CN102056602A (zh) | 决奈达隆用于预防心脏复律 | |
| CN109646438A (zh) | 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| EP2184284B1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient | |
| US9186363B1 (en) | Pharmaceutical composition and method for treating age-related macular degeneration | |
| US20240277670A1 (en) | Safe use of mmp-12 inhibitor | |
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 | |
| Kaur et al. | A comparative study of therapeutic effects and tolerability profile of cilnidipine versus amlodipine in mild to moderate essential hypertension | |
| JP2016011267A (ja) | 口腔内保湿組成物 | |
| CN102488676B (zh) | 替普瑞酮在制备预防和/或治疗抑郁症药物中的应用 | |
| WO2013062441A1 (ru) | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения | |
| Tab | enoxacin (C) 400 mg x 1 dose |